London, July 2, 2026, 22:01 BST
- Kromek Group Plc (LON:KMK) closed up 7.23% on Thursday, last changing hands at 8.90p at 16:35:29. Volume was 801,192 shares.
- FTSE AIM All-Share rose 0.18%. Kromek finished the session roughly 7 points up on the small-cap index.
- Kromek’s FY26 consensus points to second-half revenue of around £12.2 million, with the company heading for a pretax loss of about £0.95 million following a profitable start to the year in the first half.
Kromek Group Plc (LON:KMK) jumped over 7% in London on Thursday. The AIM-listed detector tech stock moved without any new regulatory filing over the last two days, bringing attention back to how much of its first-half earnings came from Siemens Healthineers (ETR:SHL), and if that level can hold up in the second half.
Kromek traded at 8.70p to sell and 9.00p to buy on AJ Bell, up 0.60p, or 7.23%. Volume came in at 801,192 shares. Market cap was £58.32 million. The last printed trade showed 8.90p at 16:35:29.
| July 2 tape | Kromek | Benchmark |
|---|---|---|
| Price/change | Last at 8.90p, up 7.23% | FTSE AIM All-Share added 0.18% |
| Day range | Traded between 8.00p and 8.95p | Moved from 773.05 up to 779.71 |
| Volume | Shares traded: 801,192 | n/a |
| Market value | Valued at £58.32 mln | n/a |
The FTSE AIM All-Share was quoted at 777.45, up 0.18%, on Google Finance at 16:50 BST. The site lists the index’s 52-week range from 693.87 to 837.43.
The shares remain far from their one-year peak. AJ Bell said Kromek’s top for the year was 13.00p, and the low was 4.70p. Thursday, the stock closed at 8.90p, putting it 31.5% under the high and up 89.4% from the low.
For investors, the key number is the profit bridge. Kromek posted revenue of £15.0 million and pretax profit of £3.1 million for the first half ended Oct. 31, 2025. Back in May, it said full-year 2026 revenue and pretax profit were expected to match consensus figures of £27.2 million and £2.15 million.
| Kromek FY26 bridge | H1 actual | FY26 consensus | Implied H2 at consensus |
|---|---|---|---|
| Revenue | £15.0 mln | £27.2 mln | £12.2 mln |
| Pretax profit | £3.1 mln | £2.15 mln | £(0.95) mln |
| New H2 orders | n/a | £8.8 mln booked in H2 | some shipped this year |
The share reaction stands out because consensus had the second half coming in with less revenue than the first and a pretax loss. Kromek said it landed £8.8 million in new orders for its CBRN Detection and Advanced Imaging units in H2, much of that shipped before year-end.
The Siemens Healthineers deal supported results in the first half. Advanced Imaging booked £10.8 million in revenue, but just £2.5 million if Siemens is stripped out—putting Siemens-related revenue for the unit at around £8.3 million. Revenue for CBRN Detection jumped to £4.3 million, more than twice last year’s figure.
Kromek CEO Arnab Basu said in the January interim update that sales in the CBRN unit more than doubled for the period. He also noted Advanced Imaging clients were getting ready for next-gen scanners.
Kromek’s valuation is now tied to how well the post-Siemens business holds up into FY27. MarketScreener lists the company’s value just under £58.31 million, with forecast P/Es at 28.7 for 2026 and 68.5 for 2027.
Kromek has a dilution factor traders are watching. The company said on June 4 it gave out 15.57 million LTIP awards to exec directors, with vesting depending on relative TSR vs the FTSE AIM All-Share. It also said that as of June 3, there were options and LTIPs out for 76.64 million shares, or 11.7% of its issued share capital.
The most recent RNS updates include the June 4 LTIP release, a new investor hub on June 2, a PDMR and director shareholding along with an equity issue on June 1, and the trading update from May 12.
